pembrolizumab
merck
['nsclc', 'keynote-407', 'sclc', 'pembro', 'medsir']
keynote-407 5y update: 1l pembro+chemo continued to demonstrate prolonged os and pfs vs pbp+chemo without increased toxicity for metastatic squamous nsclc. mos: 17.2 mo vs 11.6, 5-yos: 18.4% vs 9.7%, orr: 90.9%, 3-yos after 35 cycles: 69.5%.
#silvianovello at #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM